Coronary disease & ACSCohort study
Abbreviated dual antiplatelet therapy after percutaneous coronary intervention with drug coated balloons in acute coronary syndromes: insights from the SWEDEHEART registry
- nationwide registry-based analysis
- inverse-probability-of-treatment-weighted Cox regression
Authors' conclusion
In this nationwide registry-based analysis, abbreviated DAPT following DCB-only PCI in ACS was not associated with a statistically significant difference in NACE. However, the confidence intervals were wide and did not exclude clinically meaningful harm. The findings should be regarded as hypothesis-generating and indicate the need for more comprehensive evidence before abbreviated DAPT is routinely adopted in this setting.
Study context
- Population
- Patients with acute coronary syndromes treated exclusively with drug-coated balloons (DCBs), enrolled in the SWEDEHEART registry between June 2013 and February 2022, discharged with ticagrelorabbreviated DAPT 141 · standard DAPT 986
- Participants
- 1,128 patients
- Exposure
- abbreviated DAPT vs standard DAPT
- abbreviated DAPTn = 141
- standard DAPTn = 986
- Outcome
- net adverse clinical events (NACE): first occurrence of all-cause death, stroke, myocardial infarction, or major bleeding
- Follow-up
- 1 year from discharge date
Main finding
As reported in the abstract
Weighted hazard ratio
1.29
95% CI 0.81–2.03
P = 0.28
Events by group
abbreviated DAPT
weighted 17.8%
25 of 141
standard DAPT
weighted 13.8%
133 of 986
Observational data: associations, not effects.
Original publication
Summarised from the published abstract; every number is checked against it